Perspective Therapeutics, Inc. (CATX)

+0.028 (4.59%)
Mar 31, 2023, 4:00 PM EDT - Market closed
Market Cap 90.64M
Revenue (ttm) 9.95M
Net Income (ttm) -9.10M
Shares Out 142.07M
EPS (ttm) -0.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 415,388
Open 0.610
Previous Close 0.610
Day's Range 0.600 - 0.638
52-Week Range 0.192 - 0.673
Beta n/a
Analysts Buy
Price Target 1.02 (+59.88%)
Earnings Date May 9, 2023

About CATX

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly know... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 1983
Employees 66
Ticker Symbol CATX
Full Company Profile

Financial Performance

In 2022, CATX's revenue was $10.80 million, an increase of 7.38% compared to the previous year's $10.05 million. Losses were -$7.27 million, 114.5% more than in 2021.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for CATX stock is "Buy." The 12-month stock price forecast is $1.02, which is an increase of 59.88% from the latest price.

Price Target
(59.88% upside)
Analyst Consensus: Buy
Stock Forecasts


Perspective Therapeutics and PharmaLogic announce collaboration for the development and production of theranostics for cancer care

BOCA RATON, Fla. and RICHLAND, Wash., March 14, 2023 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a contract development and manufacturing organization and radiopharmac...

2 weeks ago - PRNewsWire